Good price action | CALA Message Board Posts

Calithera Biosciences, Inc.

  CALA website

CALA   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  384 of 1733  at  1/9/2017 6:54:46 PM  by

wilderguide


 In response to msg 383 by  KahnBoonie
view thread

Re: Good price action

I pulled this off the ASCO Post dated April 25, 2016 - Emerging strategies in TNBC:

http://www.ascopost.com/issues/april-25-2016/novel-strategies-emerging-for-triple-negative-breast-cancer/

Lots of good targets discussed here, and it strikes me that moving 839 forward in TNBC may not be prudent with paclitaxel. Ongoing evidence suggests nab-paclitaxel has logistical advantages, fewer AEs, plus higher PCR rates. Additionally, targeting AR with Xtamdi has shown solid ORR, PR, and stable disease in early TNBC trial. In a nutshell, I feel paclitaxel therapy is getting left behind quickly. No point in setting your harness to a dinosaur.. 839 plus Xtandi ? 839 plus nab-pax..??

Recent pubs addressing glutamine-addicted disease, Warburg effect, and importance of tumor microenvironment homeostasis in cancer treatment seem to be gaining in velocity. Lots of new reading just since the holidays. I'll post more on this as I can.


     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 110
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
388 Re: Good price action wilderguide 2 1/9/2017 10:02:15 PM


About Us    Contact Us    Follow Us on Twitter    Members Directory    Help Center    Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
2003-2016 Investorvillage.com. All rights reserved. User Agreement
   
Financial Market Data provided by
.

Loading...